Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID)

Authors
Masuzawa, M Mochida, N Amano, T Fujimura, T Hamada, Y Tamauchi, H Sakurai, Y Nishiyama, S Katsuoka, K
Citation
M. Masuzawa et al., Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID), J DERMA SCI, 27(2), 2001, pp. 88-94
Citations number
19
Categorie Soggetti
Dermatology
Journal title
JOURNAL OF DERMATOLOGICAL SCIENCE
ISSN journal
09231811 → ACNP
Volume
27
Issue
2
Year of publication
2001
Pages
88 - 94
Database
ISI
SICI code
0923-1811(200110)27:2<88:EORIIF>2.0.ZU;2-B
Abstract
We treated the patients with cutaneous hemangiosarcoma with recombinant int erleukin-2 (rIL-2) immunotherapy that showed clear therapeutic effects. Thi s immunotherapy is popular for the treatment of hemangiosarcoma in Japan. T he purpose of this study is to clarify the clinical effects in an animal ex periment. After establishing a SCID mouse model of human hemangiosarcoma WB -SCID, we used this model to investigate anti-tumor effects of rIL-2 and LA K cells. We demonstrated that hemangiosarcoma cells are LAK-sensitive, and LAK cells induced by rIL-2 suppress the growth of hemangiosarcoma. Our resu lts may assure the clinical effects of rIL-2 immunotherapy on hemangiosarco ma. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.